Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IPH 4102

Drug Profile

IPH 4102

Alternative Names: Anti-KIR3DL2 cytotoxic mAb; IPH 41; IPH4102

Latest Information Update: 30 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Genoa
  • Developer Innate Pharma
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; KIR3DL2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cutaneous T-cell lymphoma

Most Recent Events

  • 29 Jan 2019 IPH 4102 receives Fast Track designation for Cutaneous T-cell lymphoma [IV] (Second-line therapy or greater) in USA
  • 05 Dec 2018 IPH 4102 is still in phase I trials for Cutaneous T-cell lymphoma (Second-line therapy or greater) in France, Netherlands, USA and United Kingdom
  • 03 Dec 2018 Updated adverse events data from a phase I trial in Cutaneous T-cell lymphoma (Second-line therapy or greater) presented at the 60th Annual Meeting of the American Society of Haematology (ASH-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top